Zynex

OverviewSuggest Edit

Zynex is a company that designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include an electrical nerve stimulation device, and electromyography triggered an electrical stimulation device, as well as a device for the treatment of female urinary incontinence.
TypePublic
Founded1996
HQEnglewood, CO, USMap
Websitezynex.com
Employee Ratings3.6More
View Jobs (34)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)283(+56%)
Job Openings34
Revenue (FY, 2020)$80.1 M(+77%)
Share Price (Mar 2021)$14.8
Cybersecurity ratingAMore

Key People/Management at Zynex

Thomas Sandgaard

Thomas Sandgaard

Chairman of the Board, President, and Chief Executive Officer
Dan Moorhead

Dan Moorhead

Chief Financial Officer
Joseph Papandrea

Joseph Papandrea

Chief Operating Officer
Chelle van Burkleo

Chelle van Burkleo

VP of Sales
Raelynn Maloney

Raelynn Maloney

Director of Communications and Organizational Development
Anna Lucsok

Anna Lucsok

VP of Reimbursement
Show more

Zynex Office Locations

Zynex has offices in Englewood and Lone Tree
Englewood, CO, US (HQ)
9555 Maroon Cir
Lone Tree, CO, US
9990 Park Meadows Dr
Show all (2)

Zynex Financials and Metrics

Zynex Revenue

Embed Graph
View revenue for all periods
Zynex's revenue was reported to be $80.12 m in FY, 2020
USD

Revenue (FY, 2020)

80.1m

Gross profit (FY, 2020)

62.7m

Gross profit margin (FY, 2020), %

78.3%

Net income (FY, 2020)

9.1m

EBIT (FY, 2020)

10.2m

Market capitalization (30-Mar-2021)

514.0m

Closing stock price (30-Mar-2021)

14.8

Cash (31-Dec-2020)

39.2m

EV

482.1m
Zynex's current market capitalization is $514 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

34.1m39.7m21.7m11.1m11.6m13.3m23.4m31.9m45.5m80.1m

Cost of goods sold

7.4m8.8m8.1m4.2m4.9m3.5m4.8m6.0m8.8m17.4m

Gross profit

26.8m30.9m13.5m6.9m6.7m9.8m18.6m25.9m36.7m62.7m

Gross profit Margin, %

78%78%62%62%58%74%79%81%81%78%
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

8.4m9.4m8.9m10.0m10.1m7.7m5.5m5.2m3.2m1.3m4.4m3.2m3.1m2.7m3.5m3.3m3.6m3.4m5.0m6.8m6.9m7.6m8.1m9.2m10.3m11.8m15.2m19.3m20.0m

Cost of goods sold

1.7m1.9m1.8m1.8m2.2m2.2m1.9m1.5m997.0k903.0k1.2m1.1m1.1m726.0k983.0k941.0k880.0k923.0k1.0m1.3m1.2m1.3m1.6m1.8m1.9m2.3m3.4m4.1m4.3m

Gross profit

6.7m7.5m7.1m8.2m7.9m5.5m3.6m3.6m2.2m446.0k3.2m2.1m2.0m1.9m2.5m2.3m2.7m2.5m4.0m5.5m5.6m6.2m6.5m7.4m8.3m9.6m11.8m15.2m15.7m

Gross profit Margin, %

79%79%80%82%78%71%66%70%69%33%73%65%65%73%72%71%76%73%80%80%82%82%80%81%81%81%78%79%79%
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

789.0k823.0k323.0k63.0k8.0k247.0k5.6m10.1m14.0m39.2m

Accounts Receivable

11.0m12.2m7.0m3.2m2.4m3.0m2.2m2.8m5.8m13.8m

Prepaid Expenses

293.0k243.0k346.0k250.0k27.0k40.0k198.0k570.0k315.0k1.4m

Inventories

4.6m6.2m5.0m1.9m305.0k107.0k423.0k837.0k2.4m8.6m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

783.0k761.0k742.0k623.0k843.0k681.0k445.0k468.0k189.0k311.0k319.0k348.0k87.0k41.0k24.0k29.0k91.0k462.0k140.0k2.6m4.4m6.3m8.1m9.4m10.1m11.9m14.6m16.9m41.2m

Accounts Receivable

9.5m10.8m11.6m12.1m12.3m11.2m9.8m8.8m6.3m5.0m4.5m2.9m2.7m2.8m3.2m3.2m4.0m2.9m2.5m2.4m2.7m2.9m2.9m3.1m3.5m4.3m6.5m7.3m9.4m

Prepaid Expenses

136.0k146.0k304.0k202.0k210.0k256.0k194.0k178.0k244.0k173.0k37.0k191.0k130.0k40.0k20.0k123.0k28.0k148.0k125.0k211.0k615.0k579.0k364.0k738.0k833.0k321.0k1.1m804.0k1.1m

Inventories

3.8m4.3m5.6m6.6m6.7m6.3m5.8m6.1m5.0m2.6m2.5m1.6m1.4m1.1m173.0k164.0k96.0k128.0k178.0k358.0k710.0k518.0k796.0k968.0k1.3m2.1m3.4m4.7m5.9m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

1.6m1.6m(7.3m)(6.2m)(2.9m)69.0k7.4m9.6m9.5m9.1m

Depreciation and Amortization

806.0k864.0k839.0k660.0k424.0k435.0k286.0k448.0k778.0k1.6m

Inventories

(1.0m)(2.1m)(279.0k)726.0k1.6m198.0k(316.0k)(414.0k)(2.4m)(7.3m)

Accounts Payable

876.0k(132.0k)686.0k(199.0k)(67.0k)402.0k(1.2m)(515.0k)785.0k3.8m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

374.0k965.0k320.0k793.0k1.2m(304.0k)(2.0m)(2.8m)(1.4m)(7.0m)(6.7m)2.9m6.0m7.3m

Depreciation and Amortization

389.0k594.0k213.0k432.0k647.0k213.0k417.0k647.0k156.0k309.0k469.0k252.0k537.0k1.0m

Inventories

(93.0k)(791.0k)(995.0k)(2.1m)(2.3m)(181.0k)123.0k(265.0k)(23.0k)400.0k186.0k(1.5m)(2.4m)(4.3m)

Accounts Payable

145.0k848.0k335.0k516.0k264.0k(382.0k)51.0k232.0k162.0k258.0k2.0k162.0k189.0k1.6m
show all
USDQ2, 2011

Financial Leverage

2.1 x
Show all financial metrics

Zynex Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

Learn more about our premium products
SecurityScorecard logo

Zynex Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

Learn more about our premium products
CSRHub logo

Zynex Online and Social Media Presence

Zynex's Trends

Embed Graph

Zynex News and Updates

October 23, 2020

Zynex Appoints Neil Friery as President and Chief Operating Officer of Monitoring Solutions Division

ENGLEWOOD, Colo., Oct. 23, 2020 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics today...
July 15, 2020

Zynex, Inc. Prices Public Offering of Common Stock

ENGLEWOOD, Colo., July 14, 2020 /PRNewswire/ -- Zynex, Inc. ("Zynex") (Nasdaq: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological...
December 02, 2019

Zynex to Present at the Piper Jaffray 31st Annual Healthcare Conference

ENGLEWOOD, Colo., Dec. 2, 2019 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics today...
October 02, 2019

Zynex Announces 95% Order Growth

ENGLEWOOD, Colo., Oct. 2, 2019 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today...
June 12, 2019

Zynex to Present at Raymond James Life Sciences and MedTech Conference

ENGLEWOOD, Colo., June 12, 2019 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics today...
February 07, 2019

Zynex Announces Uplisting to The Nasdaq Capital Market

ENGLEWOOD, Colo., Feb. 7, 2019 /PRNewswire/ -- Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, is...
Show more

Zynex Blogs

April 09, 2021

Zynex Growth Leads to New Corporate Headquarters

March 30, 2021

Zynex Recognized as the Sixth Largest Biotechnology/Bioscience Company in Colorado

March 08, 2021

Zynex Announces Share Buyback Program

February 25, 2021

Zynex Announces 2020 Fourth Quarter and Full Year Earnings

February 18, 2021

Zynex Schedules 2020 Fourth Quarter and Full-Year Earnings Call

January 28, 2021

Zynex Appoints Anna Lucsok as Chief Operating Officer of Zynex Medical

Show more

 Zynex Frequently Asked Questions

  • When was Zynex founded?

    Zynex was founded in 1996.

  • Who are Zynex key executives?

    Zynex's key executives are Thomas Sandgaard, Dan Moorhead and Joseph Papandrea.

  • How many employees does Zynex have?

    Zynex has 283 employees.

  • What is Zynex revenue?

    Latest Zynex annual revenue is $80.1 m.

  • What is Zynex revenue per employee?

    Latest Zynex revenue per employee is $283.1 k.

  • Who are Zynex competitors?

    Competitors of Zynex include Haohai Biological Technology, Swiss Precision Diagnostics and Lobe.

  • Where is Zynex headquarters?

    Zynex headquarters is located at 9555 Maroon Cir, Englewood.

  • Where are Zynex offices?

    Zynex has offices in Englewood and Lone Tree.

  • How many offices does Zynex have?

    Zynex has 2 offices.